Navigation Links
Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
Date:7/27/2009

CALGARY, July 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that with the support of its contract manufacturer, SAFC Pharma(R), a Division of Sigma-Aldrich Corporation, it has successfully completed an initial 100-litre production run of REOLYSIN under cGMP conditions. This run is anticipated to be the first of a series to be completed over the next several years as Oncolytics provides product for its existing clinical trials and continues preparations toward commercial launch of REOLYSIN.

"The manufacturing program is an integral part of the Company's development plan for REOLYSIN," said Dr. Matt Coffey, Chief Operating Officer of Oncolytics. "With the clinical results reported to date and the expected initiation of our pivotal program this year, keeping pace with the manufacturing process is critical."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the sufficiency of the 100 litre cGMP manufacturing process, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
2. Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
3. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
4. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
5. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
6. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
7. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
8. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
9. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
10. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
11. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):